Hypertension Clinical Trials in Houston

Showing 141-160 of 181 trials

Physician Uncertainty Reduction for Hypertension

NCT00201084

The purpose of this study is to test the theory that a major factor in poor blood pressure (BP) control is that physicians fail to intensify antihypertensive therapy for their patients.

Cardiovascular DiseasesHeart DiseasesHypertension

Baylor College of Medicine670 participantsStarted Sep 2004

Houston, Texas, United States

COMPLETEDPhase 4< 1 mile

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289

The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension (SBP\>=160 mmHg and Diastolic Blood Pressure(DBP)\>=100 mmHg).

Hypertension

Boehringer Ingelheim894 participantsStarted Jun 2009

Athens, Alabama, United States • Mobile, Alabama, United States • Lomita, California, United States +103 more locations

Physician Uncertainty Reduction for Hypertension

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Hypertension Trials in Other Cities

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

Secondary Prevention of Small Subcortical Strokes Trial

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch

Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)

Other Conditions in Houston